SFM
XENE icon

Sphera Funds Management’s Xenon Pharmaceuticals XENE Stock Holding History

Sphera Funds Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-82,400
Closed -$2.81M – 109
2023
Q3 		$2.81M Buy
+82,400
New +$3.08M 0.51% 59

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sphera Funds Management's XENE Position: Q1 2026 in Review

Sphera Funds Management opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2026: 127,000 shares worth $7.39M. The stake represents 1.17% of the portfolio and ranks #24 among its holdings. This is a return to the name: Sphera Funds Management previously reported a position in XENE as recently as Q1 2025.

Sphera Funds Management first reported a position in XENE in Q3 2016 and has held it in 15 quarters since. The position peaked at $51.4M in Q2 2021. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Sphera Funds Management held 127,000 shares of Xenon Pharmaceuticals worth $7.39M as of Q1 2026.
  • Xenon Pharmaceuticals was a new Sphera Funds Management position in Q1 2026.
  • Xenon Pharmaceuticals made up 1.17% of Sphera Funds Management's portfolio in Q1 2026, its #24 holding.
  • Sphera Funds Management first reported a position in Xenon Pharmaceuticals in Q3 2016 and has held it in 15 quarters since.
  • Sphera Funds Management's Xenon Pharmaceuticals position peaked at $51.4M in Q2 2021.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.